Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +49.35%
#3 Glidr Glidr +35.94%
#4 Cysic Cysic +24.17%
#5 Nockchain Nockchain +17.60%
#6 Nillion Nillion +15.06%
#7 FOLKS FOLKS +14.14%
#8 Tutorial Tutorial +13.17%
#9 Humanity Humanity +13.15%
#10 Velvet Velvet +13.00%
Coin of the day
EXOD EXOD
설정
언어
한국어
통화
USD
테마
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
주식 순위 #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
주가
$0.051239
마지막 동기화: 2025-11-24
시가총액
$1.38M
변동 (1일)
-4.48%
변동 (1년)
-54.57%
국가
NO
거래 BerGenBio ASA (BGBIO)

카테고리

Healthcare
BerGenBio ASA (BGBIO)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
BerGenBio ASA의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
BerGenBio ASA의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE